Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 78   

Articles published

ARNA 4.51 -0.24 (-5.05%)
price chart
Why Arena Pharmaceuticals, Inc. Shares Jumped 24% in January
What: Shares of Arena Pharmaceuticals (NASDAQ: ARNA ) , a biopharmaceutical company primarily focused on developing therapies for weight management and to treat autoimmune diseases, jumped 24% in January per S&P Capital IQ after reporting ...
Will Arena Pharmaceuticals (ARNA) Disappoint on Q4 Earnings?
Arena Pharmaceuticals, Inc. (ARNA - Snapshot Report) is scheduled to report fourth-quarter 2014 results on Mar 2. Last quarter, the company posted a positive earnings surprise of 61.54%.
Will Arena Pharmaceuticals (ARNA) Disappoint on Q4 Earnings? - Analyst Blog  Nasdaq
Arena Pharmaceuticals' Belviq Set To Surge In 2015
It might also be said that, when examining cyclical trends in any kind of market, those that learn from history may be better positioned to take advantage of a repeat performance.
Arena Pharmaceuticals, Inc. Analyst Rating Update
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has received a Neutral rating from research analysts at Zacks with a rating of 3. The company has been rated an average of 2.29 by 7 Wall Street Analysts.
Price Target Update on Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) should head towards $6.83 per share according to 6 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $5 per share.
Share Price of Arena Pharmaceuticals, Inc. Drops by -3.01%
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has dropped 3.01% during the past week, however, the bigger picture is still very bullish; the shares have posted positive gains of 4.64% in the last 4 weeks.
Arena Pharmaceuticals, Inc. Registers High Short Interest
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): Each share of Arena Pharmaceuticals Inc is priced at $4.67, which is 36.5% below the 52-week high.
Arena's Belviq Scripts Spike - Maintaining This Trajectory Important
Arena (NASDAQ:ARNA) investors had something to celebrate this past week when script sales of the anti-obesity drug Belviq were released by IMS Health.
Arena Pharmaceuticals, Inc. Short Interest Climbs by 0.2%
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), In a major negative the short interest in Arena Pharmaceuticals, Inc. shot up by 0.2% or 68,778 shares. The final shorts are 15.6% of the total floated shares. The positions increased from 37,730,047 shares on ...
Healthcare Sector Movers: Arena Pharmaceuticals, Inc. (ARNA), Acorda ...  WallStreet Scope
Stocks to Track - Cypress Semiconductor (CY), ZIOPHARM Oncology (ZIOP ...  Techsonian (press release)
Arena Pharmaceuticals, Inc. Registers High Short Percent of Float
Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) are trading at $4.33. The price is 41.2% off the 52-week high and 24.7% off the 52-week low.
Piper Jaffray Lowers Price Target On Arena Pharmaceuticals (ARNA) By 6.25%  Bidness ETC
Brokerage Firm Initiation and Price Target on Arena Pharmaceuticals, Inc.  Wall Street Pulse